Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders

Marius Ringelstein, MD,* Ilya Ayzenberg, MD,* Gero Lindenblatt, MD, Katinka Fischer, MSc, Anna Gahlen, MD, Giovanni Novi, MD, Helen Hayward-Könnecke, MD, Sven Schipling, MD, Paulus S. Rommer, MD, Barbara Kornek, MD, Tobias Zravz, MD, Damien Biotti, MD, Jonathan Ciron, MD, Bertrand Audoin, MD, Achim Berthele, MD, Katrin Gighuber, MD, Helene Zephir, MD, Tania Kümpfel, MD, Robert Berger, MD, Joachim Röther, MD, Vivien Häußler, MD, Jan-Patrick Stellmann, MD, Daniel Whittam, MD, Anu Jacob, MD, Markus Kraemer, MD, Antoine Gueguen, MD, Romain Deschamps, MD, Antonios Bayas, MD, Martin W. Hümmer, MD, Corinna Trebst, MD, Axel Haarmann, MD, Sven Jarius, MD, Brigitte Wildemann, MD, Matthias Grothe, MD, Nadja Siebert, MD, Klemens Ruprecht, MD, Friedemann Paul, MD, Nicolas Collongues, MD, Romain Marignier, MD, Michael Levy, MD, Michael Karenfort, MD, Michael Deppe, PhD, Philipp Albrecht, MD, Kerstin Hellwig, MD, Ralf Gold, MD, Hans-Peter Hartung, MD, Sven G. Meuth, MD, Ingo Kleiter, MD,* Orhan Aktas, MD,* on behalf of the Neuromyelitis Optica Study Group (NEMOS)

Neural Neuroimmunol Neuroinflamm 2022;9:e1100. doi:10.1212/NXI.0000000000001100

Abstract

Background and Objectives
To evaluate the long-term safety and efficacy of tocilizumab (TCZ), a humanized anti–interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein–IgG–associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD).

Methods
Annualized relapse rate (ARR), Expanded Disability Status Scale score, MRI, autoantibody titers, pain, and adverse events were retrospectively evaluated in 57 patients with MOGAD (n = 14), aquaporin-4 (AQP4)-IgG seropositive (n = 36), and seronegative NMOSD (n = 7; 12%), switched to TCZ from previous immunotherapies, particularly rituximab.

Results
Patients received TCZ for 23.8 months (median; interquartile range 13.0–51.1 months), with an IV dose of 8.0 mg/kg (median; range 6–12 mg/kg) every 31.6 days (mean; range 26–44 days).

*These authors contributed equally to this work.

Department of Neurology (M.R., K.F., M.K., P.A., H.P.H., S.G.M., O.A.), Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurology (M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University Düsseldorf; Department of Neurology (I.A., A.G., K.H., R.G., I.K.), St. Josef-Hospital, Ruhr University Bochum, Germany; Department of Neurology (I.A.), Sechenov First Moscow State Medical University, Russia; Department of Neurology (G.L.), Johanna Eileen Hospital, Neuss, Germany; Department of Neurology (G.N.), San Martino Hospital, Genova, Italy; Neuroimmunology and MS Research (H.H.K., S.S.), Department of Neurology, University Hospital Zürich, Switzerland; Department of Neurology (P.S.R., B.K., T.Z.), Medical University of Vienna, Austria; Department of Neurology (D.B., J.C.), B4 unit, CRC-SEP, Toulouse Purpan University Hospital, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) (D.B., J.C.) INSERM UMR1291-CNRS UMR5051 – Université Toulouse III, France; Aix Marseille University (B.A.), APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, Marseille, France; Technical University of Munich (A.B., K.G.), School of Medicine, Department of Neurology, Klinikum rechts der Isar, Germany; University of Lille (H.Z.), Inserm, CRC-SEP, CHU Lille, France; Institut de Clinical Neuroimmunology (T.K.), Faculty of Medicine, Ludwig Maximilian University, Munich; Department of Neurology (R.B., J.R.), Asklepios Klinik Altona, Hamburg; Department of Neurology and Institute of Neuroimmunology and MS (INIMS) (V.H.), University Medical Center Hamburg-Eppendorf, Germany; APHM, Hôpital de la Timone (J.P.S.), CEMEREM; Aix Marseille Univ, CRMBM (J.P.S), UMR 7339, Marseille, France; Department of Neurology (D.W., A.J.), The Walton Centre, Liverpool, United Kingdom; the Cleveland Clinic Abu Dhabi, (A.J.) UAE; Department of Neurology (M.K.), Alfred Krupp Hospital, Essen, Germany; Department of Neurology (A.G., R.D.), Fondation Ophthalmologique Adolphe de Rothschild, Paris, France; Department of Neurology (A.B.), Universitätsklinikum Augsburg; Department of Neurology (M.W.H., C.T.), Hannover Medical School; Department of Neurology (A.H.), University of Würzburg; Molecular Neuroimmunology Group (S.J., B.W.), Department of Neurology, University of Heidelberg; Department of Neurology (M.G.), University Hospital Greifswald; NeuroCure Clinical Research Center and Experimental and Clinical Research Center (N.L., F.P.), Max Delbrueck Center for Molecular Medicine and Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (K.R.), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin; Department of Neurology (N.C.), University Hospital Strasbourg; Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation – Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, France; Department of Neurology (M.L.), Massachusetts General Hospital and Harvard University School, Boston; Department of General Pediatrics (M.K.), Neonatology and Pediatric Cardiology, Children’s Hospital, Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurology (M.D.), University Hospital, Münster; and Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempenhausen für Multiple Sklerose Kranken, Berg, Germany.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

Correspondence
Dr. Ringelstein
marius.ringelstein@med.uni-duesseldorf.de
or Dr. Aktas
orhan.aktas@med.uni-duesseldorf.de

*These authors contributed equally to this work.
Glossary

ADEM = acute disseminated encephalomyelitis; AQP4 = aquaporin-4; ARR = annualized relapse rate; AZA = azathioprine; EDSS = Expanded Disability Status Scale; IL-6 = interleukin-6; IVIG = IV immunoglobulin; LD = low-dose steroid; MMF = mycophenolate mofetil; MOG = myelin oligodendrocyte glycoprotein; MOGAD = myelin oligodendrocyte glycoprotein–IgG–associated disease; MTX = methotrexate; NMOSD = neuromyelitis optica spectrum disorder; ON = optic neuritis; RTX = rituximab; SLE = systemic lupus erythematosus; TCZ = tocilizumab; UTI = urinary tract infection.

days). For MOGAD, the median ARR decreased from 1.75 (range 0.5–5) to 0 (range 0–0.9; \( p = 0.0011 \) under TCZ. A similar effect was seen for AQP4-IgG+ (ARR reduction from 1.5 [range 0–5] to 0 [range 0–4.2]; \( p < 0.001 \) and for seronegative NMOSD (from 3.0 [range 1.0–3.0] to 0.2 [range 0–2.0]; \( p = 0.031 \)). During TCZ, 60% of all patients were relapse free (79% for MOGAD, 56% for AQP4-IgG+, and 43% for seronegative NMOSD). Disability follow-up indicated stabilization. MRI inflammatory activity decreased in MOGAD (\( p = 0.04 \); for the brain) and in AQP4-IgG+ NMOSD (\( p < 0.001 \); for the spinal cord). Chronic pain was unchanged. Regarding only patients treated with TCZ for at least 12 months (\( n = 44 \)), ARR reductions were confirmed, including the subgroups of MOGAD (\( n = 11 \)) and AQP4-IgG+ patients (\( n = 28 \)). Similarly, in the group of patients treated with TCZ for at least 12 months, 59% of them were relapse free, with 73% for MOGAD, 57% for AQP4-IgG+, and 40% for patients with seronegative NMOSD. No severe or unexpected safety signals were observed. Add-on therapy showed no advantage compared with TCZ monotherapy.

Discussion

This study provides Class III evidence that long-term TCZ therapy is safe and reduces relapse probability in MOGAD and AQP4-IgG+ NMOSD.

Myelin oligodendrocyte glycoprotein (MOG)-IgG–associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD) with or without anti–aquaporin-4 (AQP4)-IgG are antibody-mediated, chronic inflammatory CNS conditions in most cases.\(^1\)\(^-\)\(^4\) Although the clinical presentation with unilateral or bilateral optic neuritis (ON), longitudinally extensive transverse myelitis, or brain stem syndromes may be similar in MOGAD and NMOSD, demographic, clinical, imaging, and pathophysiologic findings strongly suggest the presence of 2 distinct disease entities.\(^4\)\(^-\)\(^8\) As MOGAD, excluding acute disseminated encephalomyelitis (ADEM), and NMOSD typically follow a relapsing course in adults,\(^1\(^9\) attack prevention is key to avoid disability accumulation. Recently, a variety of therapeutic strategies such as CD19/20-mediated B-cell depletion,\(^1\(^0\)\(^-\)\(^1\(^1\) complement inhibition,\(^1\(^2\) and interleukin-6 (IL-6) receptor blockade\(^1\(^3\)\(^-\)\(^1\(^4\) were successfully investigated in pivotal NMOSD trials, particularly in AQP4-IgG+ patients. Yet, insights concerning the effectiveness and safety of such agents in MOGAD are scarce.

IL-6 plays an important role in the pathophysiology of NMOSD.\(^1\(^5\) Increased levels were detected in the serum and CSF, particularly during attacks.\(^1\(^6\) IL-6 promotes the differentiation of inflammatory Th17 cells\(^1\(^7\) and the production of AQP4-IgG by B cell–derived plasmablasts in NMOSD\(^1\(^8\) and increases the permeability of the blood-brain barrier,\(^1\(^9\) facilitating CNS inflammation. The efficacy of IL-6 receptor blockade in AQP4-IgG+ NMOSD was suggested by studies using tocilizumab (TCZ) in adults and children\(^2\(^0\)\(^-\)\(^2\(^6\) and demonstrated by 2 pivotal trials of satralizumab, whereas the effect in AQP4-IgG–seronegative patients was less evident.\(^1\(^3\)\(^-\)\(^1\(^4\) As AQP4-IgG+ NMOSD and MOGAD both display antibody- and complement-mediated CNS injury and similar inflammatory CSF profiles (with elevated IL-6),\(^2\(^7\)\(^-\)\(^2\(^8\) IL-6-blockade may also be beneficial in MOGAD, supported by recent case reports.\(^2\(^3\)\(^-\)\(^2\(^5\)\(^-\)\(^2\(^9\)\(^-\)\(^3\(^3\) This retrospective multicenter study explored the safety and efficacy of TCZ in patients with MOGAD and is able to connect these findings with the effects of TCZ in classical (i.e., AQP4-IgG+) or double-seronegative NMOSD.

Patients and Previous Treatments

Fifty-seven patients with relapsing MOGAD (\( n = 14 \)),\(^3\(^4\) excluding ADEM, classical AQP4-IgG+ NMOSD (\( n = 36 \)), or double-seronegative NMOSD (\( n = 7 \)), mainly of Caucasian descent (\( n = 50 \); Table 1), from neurologic departments of 23 tertiary referral centers in Germany (\( n = 13 \), all members of the German Neuromyelitis Optica Study Group [NEMOS]), France (\( n = 5 \), all members of the NOMADMUS cohort), Austria (1), Italy (1), Switzerland (1), United Kingdom (1), and United States of America (1) were retrospectively analyzed. The evaluated TCZ treatment period ranged from December 2010 until November 2019. Regarding demographic parameters (Table 1), the mean age at disease manifestation was comparable for patients with MOGAD or AQP4-IgG+ NMOSD (35.5 or 36.1 years, respectively; \( p = 0.89 \)), as well as the age when TCZ was started (38.4 or 42.8 years, \( p = 0.35 \)). Five patients were younger than 18 years at disease manifestation, and 3 of them younger than 18 years at initiation of TCZ. Of note, patients with AQP4-IgG+
NMOSD were predominantly female, in contrast to patients with MOGAD (91% vs 35% female, respectively). Patients with AQP4-IgG+ NMOSD tended to have a longer history of disease (median 5.5 years) and were more severely affected at TCZ start (median Expanded Disability Status Scale [EDSS] score 6.25) than patients with MOGAD (median disease duration 2.2 years, \( p = 0.13 \); median EDSS score 2.75, \( p < 0.01 \)). In the MOGAD group, 7 patients (50%) fulfilled the 2015 revised international consensus diagnostic criteria for NMOSD.\(^35\) Before TCZ therapy, patients with MOGAD had had a median of 6 attacks (range 1–12 attacks) with 4.5 ON (median; range 1–10 ON) and 2.0 myelitis events (median; range 1–5 myelitis events). In the NMOSD group, 5/7 double-seronegative (71%) and 27/36 AQP4-IgG+ (75%) patients fulfilled the 2006 NMO diagnostic criteria,\(^36\) whereas all AQP4-IgG+ and double-seronegative patients fulfilled the 2015 NMOSD diagnostic criteria.\(^35\) Of note, 47/57 (83%) patients were tested for both antibodies, and none was double positive. Ten AQP4-IgG+ patients were not tested for MOG-IgG. Before TCZ, all patients had been treated with different immunotherapies following established recommendations, and, remarkably, all had received rituximab (RTX) (Table 1; Figures 1 and 2 for seropositive patients). Within the last 24, 12, and 6 months before TCZ switch, 53/57 (93%), 44/57 (77%), and 31/57 (54%) of the patients were treated with RTX, respectively. B-cell counts, collected briefly before the start of TCZ (median interval 0.9 months; interquartile range [IQR] 0.4–1.9 months), were available for 33/57 (58%) patients (25/36 [69%] AQP4-IgG+ NMOSD, 6/14 [43%] MOGAD, and 2/7 [29%] double-seronegative patients). Of these 33 patients, 28 (85%) patients (21/25 [84%] AQP4-IgG+ NMOSD, 5/6 [83%] MOGAD, and 2/2 [100%] double-seronegative patients) showed markedly reduced or depleted B cells. During the total pre-TCZ treatment phase (median duration of 2.9 years), patients had 6.0 attacks (median; range 1–30 attacks). Considering the last 2 years before TCZ start, 3.0 attacks (median; range 0–10 attacks) were recorded (Table 1).

**Methods**

All clinical and paraclinical data were analyzed retrospectively by chart review. Patients were continuously treated at the contributing centers, specialized in clinical neuroimmunology, with regular assessment of clinical (attacks, EDSS score, and pain levels) and paraclinical (MRI, AQP4- and MOG-IgG, and other laboratory tests) data. AQP4-IgG and MOG-IgG antibodies were exclusively measured by cell-based assays. The primary outcome was the annualized relapse rate (ARR). An attack was defined as definitely new neurologic symptom or clear acute worsening of previous neurologic deficits with objective clinical signs, lasting for at least 24 hours and attributed to an inflammatory CNS event, confirmed by the treating physician. Safety aspects comprised infusion-related reactions, infections, tumors, cardiovascular events, and standard laboratory tests. AQP4-IgG titers, EDSS score, and chronic pain (occurrence and intensity, classified as mild = 1, moderate = 2, or severe = 3) were assessed at TCZ start and, if available, at last follow-up during TCZ. MRI of the cervicothoracic spinal cord and the brain, evaluated at TCZ onset and last available follow-up, was classified as nonactive or active, indicated by the presence of new T2 or contrast-enhancing lesions.

**Statistical Analysis**

In general, the ARR was calculated by dividing the number of attacks within the last 2 years before TCZ switch or during TCZ treatment time by 2. However, for 19 patients, who had a TCZ pretreatment phase of <2 years (median 1.1 years), we categorically divided the total number of attacks by 2, and for 13 patients with a follow-up period of <1 year (median 0.5 years) during TCZ treatment, we divided the number of attacks by the concrete treatment duration and thus extrapolated this measure to 1 year. To avoid possible overestimation of the relapse-free proportion in the latter group, we excluded those 13 patients with TCZ treatment durations of <12 months for subgroup analyses.

In the descriptive analysis, values are given as mean or median, with the appropriate measures of dispersion (i.e., range, SD, or IQR). In all cases, the assumption of normal distribution could not be affirmed. Therefore, only nonparametrical tests were used. To test for statistically significant differences between 2 related samples like ARR before TCZ switch and ARR under TCZ therapy, the Wilcoxon signed-rank test was used. In case of paired categorical data with a dichotomous trait, the exact binomial test was used. For count data–like relapses, we also applied an unconditional Poisson regression. Statistical results are presented as \( p \) values and 95% confidence intervals. \( p \) Values <0.05 were considered to indicate statistically significant results. Because of the exploratory nature of the study, no adjustment for multiple comparisons was made. Version 3.6.3 of the R statistics package was used for statistical analysis.

**Standard Protocol Approvals, Registrations, and Patient Consents**

Ethical approval was obtained from the Institutional Review Board of the Heinrich Heine University Düsseldorf (#3419) and from each participating center by their local institutional review boards according to ICH/GCP. All patients provided written informed consent.

**Data Availability**

Anonymized data not published within this article will be made available by request from any qualified investigator.

**Results**

**TCZ Reduced ARR**

Forty-five of 57 (79%) patients switched to TCZ due to ongoing disease activity, 5/57 (9%) due side effects of prior immunotherapies (including allergic reactions on RTX in 3 patients), and 6/57 (10%) because of concomitant disease activity and adverse events. In 1 patient, the detection of...
| Table 1 Demographics and Disease Characteristics of Patients With MOGAD and NMOSD |
| --- |
| **Cohort** | MOGAD (n = 14) | AQP4-IgG+ NMOSD (n = 36) | Double seronegatives (n = 7) | Total (N = 57) |
| **Ethnicity, n (%)** | | | | |
| Caucasian | 13 (93) | 30 (83) | 7 (100) | 50 (88) |
| African | — | 3 (8) | — | 3 (5) |
| Arabian | 1 (7) | 2 (6) | — | 3 (5) |
| Latin American | — | 1 (3) | — | 1 (2) |
| **Sex, n: female/male (% female)** | | | | |
| 5/9 (35) | 33/3 (91) | 6/1 (85) | 44/13 (77) |
| **AQP4 serostatus, n: pos/neg (% positive)** | | | | |
| 0/14 (0) | 36/36 (100) | 0/7 (0) | 36/21 (63) |
| **MOG serostatus, n: pos/neg/NAa (% positive)** | | | | |
| 14/0/0 (100) | 0/26/10 (0) | 0/7/0 (0) | 14/33/10 (25) |
| **NMO based on 2006 criteria, n: yes/no (% yes)** | | | | |
| 4/10 (28) | 27/9 (75) | 5/2 (71) | 36/21 (63) |
| **NMO based on 2015 criteria, n: yes/no (% yes)** | | | | |
| 7/7 (50) | 36/0 (100) | 7/0 (100) | 50/7 (87) |
| **Age at disease manifestation, y: mean (SD)** | | | | |
| 35.5 (14.7) | 36.1 (15.2) | 42.7 (11.5) | 36.8 (14.6) |
| **Disease duration before TCZ, y: median (IQR)** | | | | |
| 2.2 (1.2–3.4) | 5.5 (1.2–9.0) | 2.4 (2.3–5.1) | 2.9 (1.3–8.2) |
| **Relapses under last immunotherapy, n: median (IQR)** | | | | |
| 1.5 (1.0–2.0) | 1.0 (1.0–2.0) | 3.0 (1.5–3) | 1.0 (1.0–2.0) |
| **Relapses during last 2 y before TCZ, n: median (IQR)** | | | | |
| 3.5 (2.2–5.0) | 3.0 (2.0–5.0) | 6.0 (2.5–6.0) | 3.0 (2.0–5.0) |
| **Age at TCZ start, y: mean (SD)** | | | | |
| 38.4 (15.0) | 42.8 (14.6) | 46.5 (10.8) | 42.2 (14.3) |
| **Number of TCZ infusions, n: mean (SD)** | | | | |
| 26.9 (21.7) | 37.6 (31.1) | 28.4 (21.9) | 34.0 (28.2) |
| **TCZ intervals, d: mean (SD)** | | | | |
| 30.8 (4.6) | 32.1 (4.6) | 30.4 (8.0) | 31.6 (4.3) |
| **TCZ treatment duration, mo: median (IQR)** | | | | |
| 16.3 (14.2–44.6) | 27.9 (12.9–53.2) | 30.4 (10.3–38.1) | 23.8 (13.0–51.1) |
| **Relapses before TCZ, n: median (IQR)** | | | | |
| 6.0 (4.2–8.0) | 5.0 (3.0–10.2) | 6.0 (5.5–8.5) | 6.0 (3.0–9.0) |
| **Relapses under TCZ, n: median (IQR)** | | | | |
| 0 (0–0) | 0 (0–1.0) | 1.0 (0–2.0) | 0 (0–1.0) |
| **EDSS score before TCZ: median (IQR)** | | | | |
| 2.75 (2.0–3.5) | 6.25 (3.0–7.6) | 5.0 (4.5–5.8) | 4.5 (3.0–7.0) |
| **EDSS score under TCZ: median (IQR)** | | | | |
| 2.0 (1.2–2.9) | 4.25 (2.5–7.0) | 5.0 (3.5–6.8) | 3.5 (2.0–6.5) |
| **Immunotherapies before TCZ, n (%):** | | | | |
| Rituximab | 14 (100) | 36 (100) | 7 (100) | 57 (100) |
| Azathioprine | 3 (21) | 13 (36) | 2 (29) | 18 (32) |
| Mycophenolate mofetil | 3 (21) | 7 (19) | 1 (14) | 11 (19) |
| Low-dose steroid monotherapy | 4 (29) | 7 (19) | 0 (0) | 11 (19) |
| Methotrexate | 1 (7) | 7 (19) | 3 (43) | 11 (19) |
| Cyclophosphamide | 2 (14) | 8 (22) | 1 (14) | 11 (19) |
| IVIG | 3 (21) | 4 (11) | 0 (0) | 7 (12) |
| Interferon-beta | 0 (0) | 5 (14) | 1 (14) | 6 (11) |
| Mitoxantrone | 0 (0) | 5 (14) | 0 (0) | 5 (9) |
| Glatiramer acetate | 0 (0) | 2 (6) | 1 (14) | 3 (5) |
| Natalizumab | 0 (0) | 1 (3) | 1 (14) | 2 (4) |
| Long-term plasma exchange | 1 (7) | 1 (3) | 0 (0) | 2 (4) |
| Alemtuzumab | 0 (0) | 1 (3) | 0 (0) | 1 (2) |
| Fingolimod | 0 (0) | 1 (3) | 0 (0) | 1 (2) |
| Cyclosporin A | 0 (0) | 1 (3) | 0 (0) | 1 (2) |
neutralizing antibodies against RTX was the reason for treatment switch. TCZ was administered IV (mean 34 infusions, range 3–109) in 56 patients (98%) at a mean interval of 31.6 days (range 26.1–44.2 days) and with a median dose of 8.0 mg/kg body weight (range 6.0–12.0 mg/kg body weight; Table 1) and subcutaneously in 1 patient (2%) with weekly injections of 162 mg. The interval from last relapse to initiation of TCZ was similar for all groups, i.e., 2.2 months (median, IQR 1.1–5.1 months) for patients with AQP4-IgG+ NMOSD, 3.2 months (1.5–4.8 months) for the MOGAD subgroup, and 2.4 months (1.7–6.2 months) for double seronegatives.

The median treatment duration was 23.8 months (IQR 13.0–51.1 months), with patients with AQP4-IgG+ NMOSD showing the longest TCZ exposure (27.1 months), compared with MOGAD (16.3 months) and double-seronegative (30.4 months) patients. In one-third of patients (20/57), TCZ was given as an add-on treatment; in 2 of them due to comorbidities (psoriasis cotreated with methotrexate [MTX]; chronic polyarthritis with oral low-dose steroids [LDSs]). Additional medications included LDS (n = 10), MTX (n = 4), mycophenolate mofetil (MMF; n = 2), azathioprine (AZA; n = 1), IV immunoglobulins (IVIG; n = 1), RTX (n = 1), and monthly high-dose steroids (HDS; n = 1), administered for <6 months in 3 patients and >6 months in 17 patients during TCZ treatment.

Initiation of TCZ was followed by a decrease of the median ARR in patients with AQP4-IgG+ NMOSD from 1.5 to 0 (p < 0.001, 95% CI 0–0.2) compared with the last 2

**Table 1** Demographics and Disease Characteristics of Patients With MOGAD and NMOSD (continued)

| Cohort          | MOGAD (n = 14) | AQP4-IgG+ NMOSD (n = 36) | Double seronegatives (n = 7) | Total (N = 57) |
|-----------------|----------------|--------------------------|-----------------------------|----------------|
| Belimumab       | 1 (7)          | 0 (0)                    | 0 (0)                       | 1 (2)          |
| Etanercept      | 0 (0)          | 1 (3)                    | 0 (0)                       | 1 (2)          |

Abbreviations: AQP4 = aquaporin-4; EDSS = Expanded Disability Status Scale; MOG = myelin oligodendrocyte glycoprotein; MOGAD = MOG-IgG-associated disorder; NMOSD = neuromyelitis optica spectrum disorder; TCZ = tocilizumab. *MOG-IgG ab not tested.

**Figure 1** Disease Courses and Individual Maintenance Immune Therapies of Patients With MOGAD

First attacks are indicated as red diamonds and further attacks as blue diamonds. IVIG = IV immunoglobulin; IVMP = IV methylprednisolone; MOG = myelin oligodendrocyte glycoprotein; MOGAD = MOG-IgG-associated disease.
years before TCZ start. Of note, patients with MOGAD showed a similar median ARR reduction from 1.75 to 0 \((p = 0.0011, 95\% \text{ CI 1.3–2.6})\). For patients with double-seronegative NMOSD, median ARR reduction was less prominent but still significant \((from 3.0 \text{ to } 0.2 \quad [p < 0.032, 95\% \text{ CI 0.3–2.8})\). For the total cohort, the median ARR decreased from 1.5 to 0 \((p < 0.001, 95\% \text{ CI 1.1–1.8}; \text{Figure 3})\). Of note, ARR reductions were also detectable when analysis was confined to those patients treated with TCZ for at least 12 months, including MOGAD and AQP4-IgG+ NMOSD, but not double-seronegative patients (Figure 3).

Regarding individual patients, 3/14 (21.4\%) patients with MOGAD (Figure 1) and 14/36 (39\%) patients with AQP4-IgG+ NMOSD (Figure 2) had at least 1 attack during TCZ treatment, and 2/14 (14.3\%) patients with MOGAD and 2/36 (5.6\%) patients with AQP4-IgG+ NMOSD showed 2 or more attacks. Sixty percent of all patients were relapse free \((79\% \text{ for MOGAD, 56}\% \text{ for AQP4-IgG+ NMOSD, and 43}\% \text{ for double-seronegative NMOSD})\). When analyzing only patients treated with TCZ for at least 12 months, 26/44 \((59\%)\) of all patients, 8/11 \((73\%)\) MOGAD, 16/28 \((57\%)\) AQP4-IgG+, and 2/5 \((40\%)\) double-seronegative patients, remained relapse free.

The median time to first relapse was 9 months \((range 0.5–47 \text{ months})\) for the whole group, 9.4 months for MOGAD \((range 9–15 \text{ months})\), 4.4 months for AQP4-IgG+ NMOSD \((range 0.5–47 \text{ months})\), and 12.2 months for double-seronegative NMOSD \((range 2.6–18.9 \text{ months})\). An unconditional Poisson regression analysis showed an average increase in relapses by 16\% per year under TCZ therapy, indicating that a relapse is not expected until after 5 years under TCZ in the total cohort \((p < 0.03)\). Moreover, double-seronegative patients had average 2.6 times the relapse counts compared with patients with AQP4-IgG+ NMOSD \((p < 0.03)\), and in the MOGAD subgroup, relapses occurred 8\% less than in AQP4-IgG+ NMOSD, which was not significant \((p = 0.86)\).

When comparing patients treated with TCZ plus add-on treatment \((20/57)\) with those on TCZ monotherapy \((37/57)\), the ARR in the add-on group was higher in the 2 years before TCZ initiation \((median 2.0 \quad \text{[IQR 1–3]} \text{ vs 1.5 \quad [IQR 1–2.5]} \text{ as well as during TCZ treatment 0.2 \quad [IQR 0–0.8] \text{ vs 0 \quad [IQR 0–0]})\). In line, freedom from relapses was achieved in 40\% of patients in the add-on group and in 78\% in the monotherapy group.

By comparing the 2 groups of patients who switched to TCZ due to ongoing disease activity or side effects, the median ARR in the first group was 2.0 \((\text{IQR 1.0–2.5})\) during the 2 years prior TCZ and was 0 \((\text{IQR 0–0.2})\) during TCZ treatment, whereas the median ARRs were 1.0 \((\text{IQR 0.5–1.0})\) and 0 \((\text{IQR 0–0})\), respectively, for both intervals in the second subgroup.

Relapsing vs Nonrelapsing Patients During TCZ Treatment
When comparing patients who relapsed vs those who did not relapse during TCZ treatment \((across the different subgroups)\), relapsing patients with AQP4-IgG+ NMOSD were younger at disease manifestation than nonrelapsing patients \((years, median, \text{relapsing vs nonrelapsing} \quad 31.4 \text{ vs } 36.4, \text{respectively}); \text{ATCZ start, MOGAD and double-seronegative patients who later relapsed were older than nonrelapsing patients, whereas relapsing and nonrelapsing AQP4-IgG+ patients had comparable age} \((years, median, \text{relapsing vs nonrelapsing} \quad 43.7 \text{ vs } 43.6, \text{MOGAD 48.5 vs } 41.2, \text{double seronegatives 50.7 vs } 37.8, \text{respectively})\). Relapsing patients had a longer disease duration than nonrelapsing in the AQP4-IgG+ and MOGAD groups \((years, median, AQP4-IgG+ \text{NMOSD } 8.76 \text{ vs } 2.93, \text{MOGAD } 3.33 \text{ vs } 2.11, \text{respectively})\). Sex had no effect on relapses in all subgroups. Under TCZ therapy, most of the myelitis and ON attacks occurred in AQP4-IgG+ NMOSD and double-seronegative patients \((AQP4-IgG+ \text{NMOSD: myelitis } [14], \text{ON } [4]; \text{MOGAD: myelitis } [2], \text{ON + myelitis } [1]; \text{double seronegatives: myelitis } [4])\).

TCZ Discontinuation
TCZ therapy was discontinued in 20/57 patients \((35.1\%); 15/36 \quad [41.7\%] \text{AQP4-IgG+, } 2/14 \quad [14\%] \text{MOGAD, and } 3/7 \quad [42.9\%] \text{double-seronegative patients}) \text{after } 14.5 \text{ treatment months} \text{(median; range } 2.9–53.9 \text{ treatment months}). \text{Of note, } 45\% \quad (9/20) \text{of them stopped TCZ for general reasons such as pregnancy, plans for pregnancy, and patient's preference} \text{(e.g., for oral medications), and } 2 \text{ patients were lost to follow-up. However, } 6 \text{ of the } 20 \text{ patients (2 AQP4-IgG+, } 3 \text{ double seronegative, and } 1 \text{ MOGAD}) \text{presented ongoing MRI activity or attacks, and } 5/20 \text{ patients (all AQP4-IgG+) discontinued due to suspected side effects such as ileus} \quad (n = 1), \text{nephritis and urticaria in the context of systemic lupus erythematosus (SLE; } n = 1), \text{psoriasis exacerbation} \quad (n = 1), \text{and upper respiratory tract infections} \quad (n = 3). \text{Two patients who stopped TCZ restarted it after completion of pregnancy and ileus treatment. Of the } 11 \text{ patients with disease activity or suspected side effects, 6 patients (55\%) received TCZ as add-on therapy, and } 5 \text{ patients (45\%) showed relapse activity, which occurred 256 days} \quad \text{(median, IQR 73–329 days} \text{) after TCZ initiation, indicating that delayed onset of efficacy may have contributed to early discontinuation.}\)

Disability
The median EDSS score significantly decreased in both seropositive groups, in MOGAD from 2.75 to 2.0 \((p < 0.031)\) and in AQP-IgG+ NMOSD from 6.25 to 4.25 \((p < 0.003)\). The median EDSS score remained stable on 5.0 in 7/7 double-seronegative patients \((p < 0.77; \text{Table 1; Figure 4})\).

When including patients with TCZ treatment duration >12 months only, the EDSS score improvement was still significant for AQP4-IgG+ NMOSD and the whole cohort (Figure 4). The EDSS score worsened in only 5/57 (9\%)
**Figure 2** Disease Courses and Individual Maintenance Immune Therapies of Patients With AQP4-IgG–Seropositive NMOSD

First attacks are indicated as red diamonds and further attacks as blue diamonds. AQP4 = aquaporin-4; IVIG = IV immunoglobulin; NMOSD = neuromyelitis optica spectrum disorder; IVMP = IV methylprednisolone; PE = plasma exchange; SLE = systemic lupus erythematosus. (a) Twelve years before tocilizumab (TCZ) initiation. (b) Twenty-four years before TCZ initiation. (c) Therapy of chronic polyarthritis 2 and a half years before TCZ initiation. (d) Fifteen years before TCZ initiation. (e and f) Sixteen years before TCZ initiation. (g) Ten and a half years before TCZ initiation. (h) Twenty-two years before TCZ initiation. (i) Eleven and a half years before TCZ initiation. (j) Psoriasis therapy; psoriasis flare-up finally remitted completely under rituximab; *loss to follow-up.
patients of the entire cohort, i.e., none of patients with MOGAD, 3/36 (8%) patients with AQP4-IgG+ NMOSD, and 2/7 (29%) double-seronegative patients.

**Pain**
Initial disease-related chronic pain was reported in 28/51 patients (55%), with a median pain intensity of 2.0 (IQR 1–3; data from 27 patients). Presence and intensity of pain were not modulated during TCZ treatment, as 25/52 patients (48%) still had ongoing chronic pain with a median intensity of 2.0 (IQR 1–3; data available from 24 patients) at last follow-up, regardless of the AQP4-IgG/MOG-IgG serostatus.

**Antibody Titers**
Regarding AQP4-IgG immunoreactivity, most patients (12/16) showed decreased or stable titers after initiation of TCZ (Figure 5 for individual courses). Longitudinally assessed MOG-IgG antibody titers were available in only 2 of 14 patients and showed a similar pattern as seen in AQP4-IgG+ NMOSD, i.e., a decrease from 1:320 to 1:32 and from 1:1,280 to 1:10, respectively.

**Magnetic Resonance Imaging**
For brain MRI, the proportion of patients with active scans (presence of new T2 or contrast-enhancing lesions) significantly decreased from 43.5% at TCZ baseline (20/46 patients with available longitudinal data at TCZ onset and follow-up) to 15.2% (7/46 patients; \( p = 0.007 \)) at last available scan, within 31.6 months (mean; range 4.2–95.8 months). This reduction was detectable for MOGAD (change from 7/13 [53.8%] to 1/13 patients [7.7%] with active scans; \( p = 0.031 \)), but not for AQP4-IgG+ (9/26 [34.6%] to 3/26 [11.5%]; \( p = 0.146 \)) or seronegative (4/7 [57.1%] to 3/7 [42.9%]; \( p = 1 \)) subgroups. For spinal cord MRI, the proportion of patients with active scans decreased from 71.4% (25/35 patients) to 28.6% (10/35; \( p = 0.00006 \)) during TCZ (mean interval 40.5 months; range 3.7–111.3). This effect was mainly driven by the AQP4-IgG+ group with a decrease from 74.1% (20/27) to 25.9% (7/27) of patients during TCZ (\( p = 0.0002 \)). For double-seronegative NMOSD and MOGAD, the proportion of patients with active scans was low and stable during TCZ.

**Safety Data**

**Clinical Events**
Infusion-related reactions occurred in 7/57 (12.3%) patients and included headache, abdominal pain, vertigo, nausea, fatigue, leg edema, rash, mild bruising, and bloating (Table 2). Infections comprised recurrent urinary tract infections (UTI, in 16% of patients), upper respiratory tract infections, common cold, bronchitis and pneumonia (in 16%), oral or lip infections (in 7%; including herpes simplex virus, ulcers, and candidiasis), erysipelas and skin lesions compatible with SLE (in 5%), and (pyelo)nephritis (in 3.5%). In 19/57 (33%) patients, 23 chronic underlying inflammatory diseases were reported, including Hashimoto thyroiditis (\( N = 7 \)), SLE (5), psoriasis (4), Sjogren syndrome (2), and vitiligo, polyarthritis, immune thrombocytopenic purpura, myasthenia gravis, and Crohn disease (1 each). Exacerbation of SLE and psoriasis

---

**Figure 3 ARR Before and During TCZ Treatment**
Box-and-whisker plots showing the median, IQR, and range of the annualized relapse rate 2 years before and during TCZ treatment for the MOGAD (A), the AQP4-IgG+ NMOSD (B) and the double seronegative (C) subgroups of patients, as well as for the total cohort (D). Each dot indicates 1 single patient. Hatched bars represent those patients who had been treated with TCZ for at least 12 months. AQP4 = aquaporin-4; ARR = annualized relapse rate; IQR = interquartile range; MOGAD = MOG-IgG-associated disease; NMOSD = neuromyelitis optica spectrum disorder; TCZ = tocilizumab.

---

For spinal cord MRI, the proportion of patients with active scans decreased from 71.4% (25/35 patients) to 28.6% (10/35; \( p = 0.00006 \)) during TCZ (mean interval 40.5 months; range 3.7–111.3). This effect was mainly driven by the AQP4-IgG+ group with a decrease from 74.1% (20/27) to 25.9% (7/27) of patients during TCZ (\( p = 0.0002 \)). For double-seronegative NMOSD and MOGAD, the proportion of patients with active scans was low and stable during TCZ.
during TCZ occurred in 4 patients (2 from each) and led to TCZ discontinuation in 2 of these 19 (11%) patients (both AQP-IgG+ NMOSD). No new cancer occurred. One case of type 1 focal nodular hyperplasia of the liver was diagnosed during TCZ. Cardiovascular events occurred in 3 patients, including a non-ST elevation myocardial infarction after the initial infusion, a deep vein thrombosis, and a slight increase in blood pressure. One death due to recurrent pneumonia occurred 2 months after discontinuation of a 6-month TCZ treatment period, but this was not regarded as treatment related by the treating physician, as the 58-year-old patient had a history of severe AQP4-IgG+ NMOSD with concomitant SLE and uterus carcinoma, including surgery and radiation.

TCZ-treated patients with additional immunotherapies suffered more frequently from pneumonia compared with the monotherapy group (18% vs 6%); other side effects like reactivation of chronic latent infections (5% vs 6%) were equally distributed in both groups.

**Laboratory Changes**

Neutropenia during TCZ treatment, with a maximum cell count reduction of 61% below the lower reference level, occurred in 10/57 (18%) patients, with 3 patients on a concomitant immunotherapy (MTX, RTX, and LDS; Table 2). However, these 10 patients had no higher frequency of common neutropenia-related conditions such as UTI, pneumonia, and other (unspecific) infections. Transient and mild to moderate increases of liver enzymes and lipase (2- to 3-fold above the upper reference level) were reported in 20/57 (35.1%) patients. In particular, alanine aminotransferase was elevated at least once in 17/57 (29.8%) patients during TCZ and increased from 28.2 U/L (mean; range 8–90 U/L; at TCZ start) to 75.6 U/L (range 21–179 U/L; \( p < 0.001 \)). Mean total cholesterol levels increased slightly during TCZ treatment from 195.3 mg/dL (n = 37/57; range

---

**Figure 4** Level of Disability Measured as EDSS Score Before and During TCZ Treatment

**Figure 5** Longitudinal Aquaporin-4-IgG Titers Before and During TCZ Treatment

| Titer change | Increased | Reduced | Unchanged |
|--------------|-----------|---------|-----------|
| AQP4-IgG titer | | | |

Individual longitudinal courses of AQP4-IgG titers (assessed by cell-based assays) for patients with AQP4-IgG–seropositive NMOSD (n = 16) are shown. Most patients (12/16) showed decreased or stable titers on initiation of TCZ; in 4/16 patients, the AQP4-IgG titer increased. AQP4 = aquaporin-4; NMOSD = neuromyelitis optica spectrum disorder; TCZ = tocilizumab.
59–311 mg/dL) to 203.8 mg/dL (n = 44/57; range 85–372 mg/dL; p = 0.5554), with no changes within the subgroups as well. Similarly, low- and high-density lipoprotein (LDL/HDL) cholesterol levels were stable during TCZ (Table 2).

Discussion

Our study designed as a multicenter real-world approach confirms and extends existing evidence, as it shows that in MOG- or AQP4-IgG–mediated inflammatory demyelinating syndromes, IL-6 blockade offers a therapeutic perspective, even if patients were exposed to standard immunotherapies before, including targeted B-cell depletion by RTX. Importantly, our data provide insights into therapeutic long-term management of these diseases, with a follow-up far beyond the observation periods in existing pivotal trials.

MOGAD in adults and NMOSD in general almost exclusively follow a relapsing disease course,3,9 emphasizing the relevance of attack prevention for disease prognosis. Considering the long-term course, MOGAD was assumed to have a less severe prognosis than NMOSD.37,38 However, recent studies indicate that retinal neuroaxonal damage and visual impairment after ON are similar in both diseases, suggesting that a higher attack rate in MOGAD, compared with fewer, but more severe ON episodes in AQP4-IgG+ NMOSD, results in comparable tissue damage.39

Previous case series in NMOSD reported that IL-6R blockade with TCZ confers beneficial effects for attack prevention in retrospective and 1 prospective case series in NMOSD.20,24,40,41 Moreover, the recent TANGO trial showed that TCZ (n = 56 patients) better prevents NMOSD attacks than azathioprine (n = 52 patients).42 Finally, 2 recent pivotal trials compared satralizumab with placebo, either as a monotherapy (SakuraStar)14 or as an add-on therapy (SakuraSky)13 and revealed that satralizumab reduces the relapse rate, particularly in AQP4-IgG+ NMOSD. However, follow-up in these trials was rather short with a range of 60–90 weeks42 and a median treatment duration in the double-blind period of 107.4
and 92.3 weeks, respectively.\textsuperscript{13,14} Moreover, real-world NMOSD patient cohorts on TCZ covered a limited number of patients (ranging from 3 to 19)\textsuperscript{20,24,40,41} and did not investigate the effects of IL-6R blockade in MOGAD. Of note, 12/36 patients with AQP4-IgG+ NMOSD from this work were previously reported in 4 TCZ-specific studies.\textsuperscript{21,22,25,26}

In our study on 57 patients including 14 individuals with MOGAD and 36 individuals with AQP4-IgG+ NMOSD, we provide real-world data with a mean and maximum treatment duration of nearly 3 and 9 years, respectively, with 65% of patients receiving TCZ as monotherapy. The mean ARR, as a primary outcome measure, significantly decreased during TCZ treatment by 80% in the total cohort and by 76% in the AQP4-IgG+ subgroup. Of note, our main results—ARR reductions in MOGAD and AQP4-IgG+ NMOSD subgroups and the whole cohort—remained stable when the analysis was restricted to patients receiving TCZ for at least 12 months. Our findings confirm the recent pivotal trials on the beneficial effects of IL-6 blockade by satralizumab in NMOSD, particularly for AQP4-IgG-seropositive patients. We also observed clinical stabilization and reduced spinal cord MRI activity in AQP4-IgG+ patients, along with decreased or stable AQP4-IgG titers in most of them, whereas pain remained constant during TCZ. The decrease of the EDSS score, spinal cord MRI activity, and AQP4-IgG titers could at least in part be explained by fact that baseline values were ascertained during the acute phase and follow-up measures mainly during remission phase while TCZ treatment. Beyond that, the AQP4-IgG titer decrease/stabilization may also be an indirect effect of the IL-6 blockade by TCZ, as IL-6 signaling promotes the autoantibody production from plasmablasts in NMOSD.\textsuperscript{18} Our clinical and imaging findings are in line with those in smaller retrospective case series and the TANGO trial.\textsuperscript{22,23,41,42} The effect on pain remains ambiguous, as it was reported in smaller case series,\textsuperscript{20,22} but was not confirmed in our study or the satralizumab SakuraSky trial.\textsuperscript{13}

Regarding the patients with double-seronegative NMOSD, we observed a significant ARR reduction, when considering all 7 patients, independently of the treatment duration, which was not reported in the pivotal trials for satralizumab and could be explained by the heterogeneity of this less-defined patient group, hampering direct comparisons.\textsuperscript{13,14}

In line with the satralizumab studies, no effect on EDSS score, pain, and, furthermore, on MRI activity, was detectable in AQP4-IgG+ NMOSD in this study.

For MOGAD, treatment recommendations are scarce, and approaches well established for AQP4-IgG+ NMOSD such as CD20-mediated B-cell depletion have shown limited efficacy in MOGAD.\textsuperscript{43-45} Another MOGAD treatment study showed that under azathioprine therapy, 14 of 17 MOG-IgG+ patients (82%) had at least 1 attack, particularly during the first 6 months and in patients without concomitant steroid therapy.\textsuperscript{3} Reports on IVIG or MTX treatment in MOGAD are so far rather anecdotal\textsuperscript{3,46}; however, recent data revealed the lowest ARR being associated with an IVIG maintenance therapy (n = 10 patients), compared with RTX, MMF, and AZA.\textsuperscript{45} Of note, recent findings in a Chinese MOGAD cohort indicate that MMF may prevent relapses, particularly with concomitant oral prednisolone.\textsuperscript{47} Compared with untreated adult patients with MOGAD, AZA, MMF, and RTX, but not MTX, mitoxantrone, and cyclophosphamide, significantly reduced the risk of new relapses and the ARR in a cohort of 125 patients.\textsuperscript{48} So far, only 14 different MOGAD patients, treated IV and/or subcutaneously with TCZ, were reported in 7 small case reports/series.\textsuperscript{25,26,29-33} 6 of these 14 patients were included in the present cohort.

Here, in our series of 14 patients with MOGAD, the ARR decreased by 93%, the median EDSS score was reduced from 2.75 to 2.0 over a mean TCZ treatment duration of 31 months, and an anti-inflammatory effect was obvious also on brain MRI. Notably, the ARR reduction persisted when considering only those patients who were treated for more than 12 months. Again, the effect on EDSS score and MRI activity was mainly driven by the fact of high disease activity at baseline and remission phase at follow-up assessment. Most patients with MOGAD (79% and 73% for the patients treated for >12 months, respectively) remained relapse free, and in 57% of them, TCZ was used as monotherapy. The remaining 6 patients were cotreated with LDS (n = 4), monthly HDS plus IVIG (n = 1), or MTX (due to psoriasis, n = 1). No effects were found on pain, which is a common symptom in MOGAD,\textsuperscript{49} and spinal cord MRI activity. A single attack during TCZ treatment occurred in 21% of patients with MOGAD, 2 or 4 attacks in 14% and 7% of patients, respectively. Our findings are in line with those of a recent study, which showed that TCZ therapy was associated with clinical and radiographic relapse freedom, resolution of eye pain, and ability to discontinue corticosteroids in a cohort of 10 patients with MOGAD over an average treatment duration of 28.6 months.\textsuperscript{31} Overall, when considering disease activity, including ARR, as well as suspected side effects during TCZ therapy, we did not observe a clear advantage of add-on treatments, supporting the use of TCZ as monotherapy.

Considering safety, adverse events occurred within the expected range based on the established use of TCZ in clinical practice. Infusion-related reactions appeared in 12% of all patients, and infections of the urinary or respiratory tract were reported with similar frequency. Of note, (re)activation or worsening of chronic latent inflammatory diseases was observed in patients with already established SLE (n = 2) and psoriasis (n = 2), indicating that these patients should be particularly monitored. Laboratory changes included mild to
moderate neutropenia in 18% and liver enzyme changes in 35% of patients. Total cholesterol, as well as HDL and LDL cholesterol levels, did not change during TCZ treatment, as expected.\textsuperscript{22}

An obvious limitation of this study is the retrospective multicenter design resulting in heterogeneity of TCZ treatment regimens and MRI protocols, as well as missing data, e.g., the lack of MOG-IgG testing in 10/36 (28%) AQP4-IgG+ patients. However, the latter issue may not be a serious limitation as co-occurrence of AQP4- and MOG-IgG at significant titers is extremely rare.\textsuperscript{50} Another constraint is the relatively small sample size, which is justifiable by the rarity of NMOSD and MOGAD on a concomitant rare and off-label treatment with TCZ. Nevertheless, we attempted to enroll all of these seldom patients from 2 of the largest cohorts in Europe, NEMOS in Germany and NOMADMUS in France, and additional patients from other countries. Moreover, because of the lack of a control cohort and the timing of the switch to TCZ (i.e., during a phase of active disease), we have to consider regression to the mean as an important limitation of our study design, as mean disease activity could decrease spontaneously even without treatment.

Despite these limitations, this largest real-world study supports the long-term safety and therapeutic relevance of the IL-6 pathway in RTX-refractory AQP4-IgG+ NMOSD for up to 9 years. Moreover, our findings suggest a similar role for MOGAD, pointing toward the need for randomized controlled trials to evaluate the efficacy of IL-6 blockade in patients with MOGAD. This study provides Class III evidence that TCZ decreases the probability of relapses in patients with refractory MOGAD and NMOSD.

Acknowledgment
The authors thank all patients and their families for contributing to our study. Contributing members of the Neuromyelitis Optica Study Group are listed in Appendix 2. MR, IA, GL, IK, and OA had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study Funding
The Neuromyelitis Optica Study Group (NEMOS) is partially funded by the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS; for NEMOS NationNMO FKZ 01GI1602).

Disclosure
M. Ringelstein received speaker honoraria from Novartis, Bayer Vital GmbH, Roche, Alexion, and Ipsen and travel reimbursement from Bayer Schering, Biogen Idec, Merck, Genzyme, Teva, Roche, and Merck. I. Ayzenberg received personal fees from Roche, Alexion, and Merck and received research support from Diamed, none related to this study. G. Lindenblatt received travel reimbursement from Bayer HealthCare, not related to this study. K. Fischer, A. Gahlen, and G. Novi report no disclosures relevant to the manuscript. H. Hayward-Könnecke received compensation for advice, lecturing, or travel support from Biogen, Genzyme, Merck, Novartis, and Teva. S. Schippling received consulting and speaker fees and travel grants from Biogen Idec, Bayer, Merck, Sanofi Genzyme/Sanoﬁ Aventis, Novartis, and Teva and research grants from Bayer, Biogen Idec, Merck Serono, Sanofi Genzyme/Sanoﬁ Aventis, and Novartis. He is currently an employee at Roche Pharmaceutical Research and Development Neuroscience and Rare Diseases. P. Rommer received speaker or consultancy honoraria from AbbVie, Alexion, Almirall, Biogen, Daiichi Sankyo, Merck, Novartis, Sanofi Genzyme, Sandoz, and Roche and research funding from Biogen, Merck, Roche, and Austrian Science Funds (KLI 837-8), none related to this study. B. Kornek received speaker honoraria from Bayer, Biogen, Celgene-BMS, Merck, Novartis, Roche, Sanofi Genzyme, and Teva and participated in advisory boards from Celgene-BMS, Merck, Novartis, Sanofi Genzyme, and Roche. No COIs related to this study. T. Zrzavy has participated in meetings sponsored by or received travel funding from Biogen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva. D. Biotti reports no disclosures relevant to the manuscript. J. Ciron received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Merck, Genzyme, and Roche, none related to this study. B. Audoin reports no disclosures relevant to the manuscript. A. Berthele has received speaker and consulting honoraria from Alexion, Biogen, Bayer HealthCare, Celgene, Merck, Novartis Pharma, and Roche, all outside the submitted work. K. Giglhuber reports no disclosures relevant to the manuscript. J. Röther received speaker honoraria and/or personal fees for advisory boards from Bayer HealthCare, Teva Pharma, Merck, Novartis Pharma, Sanofi Aventis/Genzyme, Roche Pharma, and Biogen and grant support from Novartis and Chugai Pharma in the past. R. Berger reports no disclosures relevant to the manuscript. J. Röther received speaker honoraria from Bayer Vital GmbH, Bristol Myers Squibb, Pfizer, AstraZeneca, Portola, Daiichi Sankyo, and Servier, none related to this study. V. Häußler reports no disclosures relevant to the manuscript. J.-P. Stellmann received research grants and speaker honoraria from Biogen, Genzyme, and Alexion. D. Whittam and A. Jacob report no disclosures relevant to the manuscript. H. Zéphir reports speaker honoraria, travel reimbursement, and consulting fees from Biogen Idec, Merck, Novartis, Roche, Teva, Genzyme, and Bayer Pharma and research grants from Roche, Teva, ARSEP, and LFSEP, not relevant to the manuscript. T. Kümpfel has received speaker honoraria and/or personal fees for advisory boards from Bayer HealthCare, Teva Pharma, Merck, Novartis Pharma, Sanofi Aventis/Genzyme, Roche Pharma, and Biogen and grant support from Novartis and Chugai Pharma in the past. R. Berger reports no disclosures relevant to the manuscript. J. Röther received speaker honoraria from Bayer Vital GmbH, Bristol Myers Squibb, Pfizer, AstraZeneca, Portola, Daiichi Sankyo, and Servier, none related to this study. V. Häußler reports no disclosures relevant to the manuscript. J.-P. Stellmann received research grants and speaker honoraria from Biogen, Genzyme, and Alexion. D. Whittam and A. Jacob report no disclosures relevant to the manuscript. M. Krämer received honoraria for teaching and scientific activities from Chugai Pharma, Janssen-Cilag, and Roche Pharma. A. Gueguen served as an editorial board member of Biogen Idec, Novartis, and Teva and received consulting fees from Biogen Idec, Novartis, and Teva; he received funding for...
travel from Biogen Idec, Novartis, and Teva Pharma. R. Deschamps reports no disclosures relevant to the manuscript. A. Bayas has received personal compensation from Merck Serono, Biogen, Novartis, Teva, Roche, Sanofi/Genzyme, Alexion, and Celgene and grants and congress trips and participation from Biogen, Teva, Novartis, Sanofi/Genzyme, Merck Serono, and Celgene. M.W. Hümmer reports no disclosures relevant to the manuscript. C. Trebst has received honoraria for consultation and expert testimony from Biogen Idec GmbH, Genzyme GmbH, Novartis Pharma GmbH, Merck, Chugai Pharma Germany GmbH, and Roche Pharma GmbH. None of this interfered with the current report. A. Haarmann and S. Jarius report no disclosures relevant to the manuscript. B. Wildemann received grants from the German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation, and Klaus Tschira Foundation; and received speaker honoraria and travel grants from the German Ministry for Education and Research (BMBF), Merck Serono, and Novartis. None of this interfered with the current report. N. Siebert received travel funding from Sanofi Aventis/Genzyme and speaker honoraria from Bayer AG. K. Ruprecht received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité (BIH Clinical Fellow Program), and Arthur Arnstein Foundation; received speaker honoraria and travel grants from Bayer, Biogen Idec, Merck Serono, Sanofi Aventis/Genzyme, Teva, Roche, Novartis, and The Guthy-Jackson Charitable Foundation. F. Paul serves as Academic Editor, PLoS ONE, and Associate Editor, Neurology Neuroimmunology and Neuroinflammation; is member of Novartis OCTIMS study steering committee and MedImmune/Viela Bio steering committee; reports speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, and Celgene and consultancies for Sanofi Genzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, and Merck Serono, German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combim-s.eu), Arthur Arnstein Foundation Berlin, The Guthy-Jackson Charitable Foundation, and National Multiple Sclerosis Society of the United States. N. Collongues reports no disclosures relevant to the manuscript. R. Marignier reports personal fees and nonfinancial support from Viela Bio, nonfinancial support from Merck, nonfinancial support from Biogen, personal fees and nonfinancial support from Roche, and personal fees from UCB, outside the submitted work. M. Levy received consulting fees from Alexion, Viela Bio, Genentech/Roche/Chugai, Quest Diagnostics, Mitsubishi Pharma, and UCB Pharmaceuticals. M. Karenfort received board honoraria from Novartis, not related to the content of this manuscript. M. Deppe reports no disclosures relevant to the manuscript. P. Albrecht received compensation for serving on scientific advisory boards for Ipsen, Novartis, and Biogen; he received speaker honoraria and travel support from Novartis, Teva, Biogen, Merz Pharmaceuticals, Ipsen, Allergan, Bayer HealthCare, Eisai, UCB, and GlaxoSmithKline; he received research support from Novartis, Biogen, Teva, Merz Pharmaceuticals, Ipsen, and Roche. All not related to the content of this manuscript. K. Hellwig received speaker’s board honoraria, and research support from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, and Teva. His department received grant support from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, and Teva. R. Gold received speaker’s board honoraria from Bayer Schering, Biogen Idec, CLB Behring, Genzyme, Merck Serono, Novartis, Stendhal, Talecris, and Teva. His department received grant support from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, and Teva. All not related to the content of this manuscript. H.-P. Hartung received, with approval of the Rector of Heinrich Heine University and the CEO of University of Düsseldorf Hospital, honoraria for consulting, serving on steering committees and speaking from Bayer, Biogen, GenNeuro, Genzyme, MedImmune, Merck, Novartis, Receptos Celgene, Roche, Sanofi, and Teva. S.G. Meuth receives honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer HealthCare, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut für Risikobewertung (BR), Deutsche Forschungsgemeinschaft (DFG), Else Krönener Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, and Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. I. Kleiter has received personal fees from Alexion, Biogen, Celgene, Chugai, Novartis, Merck, and Roche and received research support from Chugai and Diamed. O. Aktas has received personal fees from Alexion, Bayer HealthCare, Biogen, Celgene, Merck Serono, MedImmune, Novartis, Roche, Teva, and Zambon, outside the submitted work. Go to Neurology.org/NN for full disclosures.

Publication History
Received by Neurology: Neuroimmunology & Neuroinflammation February 8, 2021. Accepted in final form August 25, 2021.
### Appendix 1 Authors

| Name                  | Location                                      | Contribution                                                                 |
|-----------------------|-----------------------------------------------|------------------------------------------------------------------------------|
| Marius Ringelstein, MD| Heinrich Heine University, Düsseldorf, Germany| Designed and conceptualized the study; major role in the acquisition of data; analyzed the data and drafted the manuscript for intellectual content |
| Ilya Ayzenberg, MD    | Ruhr University, Bochum, Germany; Sechenov First Moscow State Medical University, Russia | Designed and conceptualized the study; major role in the acquisition of data; analyzed the data; and drafted the manuscript for intellectual content |
| Gero Lindenblatt, MD  | Johanna Etienne Hospital, Neuss, Germany      | Major role in the statistical analysis and drafted the manuscript for intellectual content |
| Katinka Fischer, M.Sc.| Heinrich Heine University, Düsseldorf, Germany| Major role in the statistical analysis and drafted the manuscript for intellectual content |
| Anna Gahlen, MD       | Ruhr University, Bochum, Germany              | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Giovanni Novi, MD     | San Martino Hospital, Genova, Italy           | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Helen Hayward-Könnecke, MD| University Hospital Zürich, Switzerland     | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Sven Schippling, MD   | University Hospital Zürich, Switzerland       | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Paulus Rommer, MD     | Medical University of Vienna, Austria         | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Barbara Kornek, MD    | Medical University of Vienna, Austria         | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Tobias Zrzavy, MD     | Medical University of Vienna, Austria         | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Damien Biotti, MD     | Université de Toulouse, France                | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Jonathan Ciron, MD    | Université de Toulouse, France                | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Bertrand Audoin, MD   | Aix Marseille University, France              | Major role in the acquisition of data and revised the manuscript for intellectual content |

### Appendix 1 (continued)

| Name                  | Location                                      | Contribution                                                                 |
|-----------------------|-----------------------------------------------|------------------------------------------------------------------------------|
| Achim Berthele, MD    | Technical University of Munich, Germany       | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Katrin Gighuber, MD   | Technical University of Munich, Germany       | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Hélène Zéphir, MD     | University of Lille, France                   | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Tania Kümpefl, MD     | Ludwig-Maximilians University, Munich, Germany| Major role in the acquisition of data and revised the manuscript for intellectual content |
| Robert Berger, MD     | Asklepios Klinik Altona, Hamburg, Germany     | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Joachim Röther, MD    | Asklepios Klinik Altona, Hamburg, Germany     | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Vivien Häußler, MD   | University Medical Center Hamburg-Eppendorf, Germany| Major role in the acquisition of data and revised the manuscript for intellectual content |
| Jan-Patrick Steilmann, MD | Hôpital de la Timone and Aix Marseille, France | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Daniel Whittam, MD    | The Walton Centre, Liverpool, United Kingdom  | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Anu Jacob, MD         | The Walton Centre, Liverpool, United Kingdom  | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Markus Kraemer, MD    | Department of Neurology, Alfred Krupp Hospital, Essen, Germany | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Antoine Gueguen, MD   | Fondation Ophtalmologique Adolphe de Rothschild, Paris, France | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Romain Deschamps, MD  | Fondation Ophtalmologique Adolphe de Rothschild, Paris, France | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Antonios Bayas, MD    | Universitätsklinikum Augsburg, Augsburg, Germany | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Martin W. Hümmer, MD  | Hannover Medical School, Hannover, Germany    | Major role in the acquisition of data and revised the manuscript for intellectual content |
### Appendix 1 (continued)

| Name                  | Location                                  | Contribution                                                                 |
|-----------------------|--------------------------------------------|------------------------------------------------------------------------------|
| Corinna Trebst, MD    | Hannover Medical School, Hannover, Germany | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Axel Haarmann, MD     | University Hospital, Würzburg, Germany    | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Sven Jarius, MD       | University of Heidelberg, Germany         | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Brigitte Wildemann, MD| University of Heidelberg, Germany         | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Matthias Grothe, MD   | University hospital Greifswald, Germany    | Analyzed the data and revised the manuscript for intellectual content         |
| Nadja Siebert, MD     | Charité Universitätsmedizin, Berlin, Germany | Analyzed the data and revised the manuscript for intellectual content         |
| Klemens Ruprecht, MD  | Charité Universitätsmedizin, Berlin, Germany | Analyzed the data and revised the manuscript for intellectual content         |
| Friedemann Paul, MD   | Charité Universitätsmedizin, Berlin, Germany | Analyzed the data and revised the manuscript for intellectual content         |
| Nicolas Collongues, MD| University Hospital Strasbourg, France     | Analyzed the data and revised the manuscript for intellectual content         |
| Romain Marignier, MD  | Pierre Wertheimer Hospices Civils de Lyon, France | Analyzed the data and revised the manuscript for intellectual content         |
| Michael Levy, MD, PhD | Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA | Analyzed the data and revised the manuscript for intellectual content         |
| Michael Karenfort, MD | Heinrich Heine University, Düsseldorf, Germany | Designed and conceptualized the study; analyzed the data; and drafted the manuscript for intellectual content |
| Michael Deppe, PhD    | University Hospital, Münster, Germany      | Major role in the statistical analysis and drafted the manuscript for intellectual content |
| Philipp Albrecht, MD  | Heinrich Heine University, Düsseldorf, Germany | Major role in the statistical analysis and drafted the manuscript for intellectual content |
| Kerstin Hellwig, MD   | Ruhr University, Bochum, Germany           | Major role in the acquisition of data and revised the manuscript for intellectual content |
| Ralf Gold             | Ruhr University, Bochum, Germany           | Analyzed the data and revised the manuscript for intellectual content         |

### Appendix 2 Coinvestigators

| Name                  | Location                                                   | Role               | Contribution                                                                                                                                 |
|-----------------------|------------------------------------------------------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Klemens Angstwurm, MD | University Hospital, Regensburg, Germany                   | Coinvestigator     | Organizational support                                                                                                                                 |
| Susanna Asseyer, MD   | Charité - Universitätsmedizin Berlin, Germany              | Coinvestigator     | Organizational support                                                                                                                                 |
| Judith Bellmann-Strobl, MD | Charité - Universitätsmedizin Berlin, Germany | Coinvestigator     | Organizational support                                                                                                                                 |
| Felix Bischof, MD     | University Hospital, Tübingen, and Nervenärztliche Gemeinschaftspraxis, Böblingen, Germany | Coinvestigator     | Organizational support                                                                                                                                 |
| Stefan Bittner, MD    | University Medical Center of the Johannes Gutenberg University, Mainz, Germany | Coinvestigator     | Organizational support                                                                                                                                 |
| Tobias Böttcher, MD   | Johanna-Odebrecht-Stiftung, Greifswald, Germany            | Coinvestigator     | Organizational support                                                                                                                                 |
| Mathias Buttmann, MD  | University of Würzburg, Germany                           | Coinvestigator     | Organizational support                                                                                                                                 |
| Ankelien Duchow       | Charité University Medicine, Berlin, Germany               | Coinvestigator     | Organizational support                                                                                                                                 |
| Barbara Ettrich, MD   | University Hospital, Leipzig, Germany                      | Coinvestigator     | Organizational support                                                                                                                                 |
| Jürgen Faiss, MD      | Asklepios Klinik, Teupitz, Germany                         | Coinvestigator     | Organizational support                                                                                                                                 |
| Benedikt Frank, MD    | University Hospital, Essen, Germany                       | Coinvestigator     | Organizational support                                                                                                                                 |

Continued
## Appendix 2 (continued)

| Name                  | Location                                      | Role         | Contribution                      |
|-----------------------|-----------------------------------------------|--------------|-----------------------------------|
| Achim Gass, MD        | University Hospital, Mannheim, Germany        | Coinvestigator | Organizational support            |
| Christian Geis, MD    | Department of Neurology, Jena University Hospital, Germany | Coinvestigator | Organizational support            |
| Kerstin Guthke, MD    | Klinikum Görlitz, Germany                    | Coinvestigator | Organizational support            |
| Bernhard Hemmer, MD   | Technical University, Munich, Germany         | Coinvestigator | Organizational support            |
| Frank Hoffmann, MD    | Krankenhaus Marthavilla, Halle, Germany      | Coinvestigator | Organizational support            |
| Olaf Hoffmann, MD     | St. Josefs-Krankenhaus, Potsdam, Germany      | Coinvestigator | Organizational support            |
| Ulrich Hofstadt-van Oy, MD | Klinikum Westfalen, Dortmund, Germany | Coinvestigator | Organizational support            |
| Jutta Junghans, MD    | Krankenhaus Marthavilla, Halle, Germany      | Coinvestigator | Organizational support            |
| Matthias Kaste, MD    | Nordwest Hospital Sanderbusch, Sande, Germany | Coinvestigator | Organizational support            |
| Barbara Kaulen, MD    | University Hospital, Hamburg, Germany         | Coinvestigator | Organizational support            |
| Peter Kern, MD        | Asklepios Klinik, Teupitz, Germany            | Coinvestigator | Organizational support            |
| Pawel Kermer, MD      | Nordwest Hospital Sanderbusch, Sande, Germany | Coinvestigator | Organizational support            |
| Christoph Kleinschnitz, MD | University Hospital, Essen, Germany | Coinvestigator | Organizational support            |
| Luisa Klotz, MD       | University Hospital, Münster, Germany         | Coinvestigator | Organizational support            |
| Wolfgang Köhler, MD   | University Hospital, Leipzig, Germany         | Coinvestigator | Organizational support            |
| Melanie Korsen, MD    | University Hospital Düsseldorf, Germany       | Coinvestigator | Organizational support            |
| Markus Kowarik, MD    | University Hospital, Tübingen, Germany        | Coinvestigator | Organizational support            |
| Markus Krumholz, MD   | University Hospital, Tübingen, Germany        | Coinvestigator | Organizational support            |
| Stefan Langel, MD     | Landeskrankenhaus Rheinhessen, Germany        | Coinvestigator | Organizational support            |
| Martin Liebetrau, MD  | St. Josefs-Hospital, Wiesbaden, Germany       | Coinvestigator | Organizational support            |
| Ralf Linker, MD       | University Hospital, Regensburg, Germany      | Coinvestigator | Organizational support            |
| De-Hyung Lee, MD      | University Hospital, Regensburg, Germany      | Coinvestigator | Organizational support            |
| Felix Luessi, MD      | University Medical Center of the Johannes Gutenberg University, Mainz, Germany | Coinvestigator | Organizational support            |
| Martin Marziniak, MD  | Isar-Amper Klinik Ost, Munich, Germany        | Coinvestigator | Organizational support            |
| Christoph Mayer, MD   | Neurologischen Gemeinschaftspraxis im Bienenkorbhaus, Frankfurt, Germany | Coinvestigator | Organizational support            |
| Stefanie Meister, MD  | University Hospital, Rostock, Germany         | Coinvestigator | Organizational support            |
| Arthur Melms, MD      | Fachartzpraxis für Neurologie und Psychiatrie, Stuttgart, Germany | Coinvestigator | Organizational support            |
| Imke Metz, MD         | University Hospital, Göttingen, Germany       | Coinvestigator | Organizational support            |
| Oliver Neuhaus, MD    | SRH Krankenhaus, Sigmaringen, Germany         | Coinvestigator | Organizational support            |
| Sabine Niehaus, MD    | Klinikum Dortmund, Germany                   | Coinvestigator | Organizational support            |
| Florence Pache, MD    | Charité University Medicine, Berlin, Germany  | Coinvestigator | Organizational support            |
| Marc Pawlitzki, MD    | University Hospital, Münster, Germany         | Coinvestigator | Organizational support            |
| Hannah Pielkoffner, MD | Ludwig-Maximilians University, Munich, Germany | Coinvestigator | Organizational support            |
| Hans-Ulrich Puhmann, MD | Schlosspark-Klinik, Berlin, Germany          | Coinvestigator | Organizational support            |
| Refik Pul, MD         | University Hospital, Essen, Germany           | Coinvestigator | Organizational support            |
| Kevin Rostäsy, MD     | Vestische Caritas-Kliniken GmbH, Datteln, Germany | Coinvestigator | Organizational support            |
| Lioba Rückriem, MD    | MediClin Hedon-Klinik, Lingen (Ems), Germany  | Coinvestigator | Organizational support            |
| Christoph Ruschil, MD | University Hospital, Tübingen, Germany        | Coinvestigator | Organizational support            |
| Matthias Schaab, MD   | University Hospital, Jena, Germany            | Coinvestigator | Organizational support            |
| Makbule Senel, MD     | University Hospital, Ulm, Germany             | Coinvestigator | Organizational support            |
| Jörn Peter Sieb, MD   | Helios Hanseklinikum, Stralsund, Germany      | Coinvestigator | Organizational support            |
| Claudia Sommer, MD    | University Hospital, Würzburg, Germany        | Coinvestigator | Organizational support            |
| Annette Spreeer, MD   | University Medical Center of the Johannes Gutenberg University, Mainz, Germany | Coinvestigator | Organizational support            |
### References

1. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica (Devic’s syndrome). *Handb Clin Neurol* 2014;122:581-599.

2. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. *J Neuroinflammation*. 2012;9:14.

3. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. *J Neuroinflammation*. 2016;13(1):280.

4. Cobo-Cabó A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. *Neurology*. 2018;90(21):e1858-e1869.

5. Salama S, Khan M, Shanechi A, Levy M, Ebudia I. MRI differences between MOG antibody disease and AQP4 NMO. *Mult Scler*. 2020;26(14):1854-1865.

6. Hacidom Y, Palace J. Time to separate MOG-Ab-associated disease from AQP4-Ab positive neuromyelitis optica spectrum disorder. *Neurology*. 2018;90(21):947-948.

7. Mader S, Kumpfel T, Meini E. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-Ab and MOG-IgG-associated diseases. *Carr Opin Neurol*. 2020;33(3):362-371.

8. Hoffberger R, Gao Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. *Acta Neuropatol*. 2020;139(5):875-892.

9. Wingerchuk DM, Pittcock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. *Neurology*. 2007;68(8):603-605.

10. Cree BAC, Bennett JL, Kim HJ, et al. Inhibilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. *Lancet*. 2019;394(10196):1352-1363.

11. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2020;19(4):298-306.

12. Pittcock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4 positive neuromyelitis optica spectrum disorder. *N Engl J Med*. 2019;381(7):614-625.

13. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. *N Engl J Med*. 2019;381(22):2114-2124.

14. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. *Lancet Neurol*. 2020;19(5):402-412.

15. Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder and multiple sclerosis. *J Neuroinflammation*. 2020;7:56.

16. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. *Mult Scler*. 2010;16(12):1443-1452.

17. Asagai M, Wu Q, Khatri B, et al. Transcriptomics and proteomics reveal a cooperation of interferon and T-helper 17 cells in neuromyelitis optica. *Nat Commun*. 2020;11(1):2856.

18. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. *Proc Natl Acad Sci U S A*. 2011;108(9):3701-3706.

19. Takeshita Y, Obermeier B, Cottereau A, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vivo. *Neuro Immunol Neurol Immunflamm*. 2017;4(1):e311.

20. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. *Neurology*. 2014;82(15):1302-1306.

21. Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. *JAMA Neurol*. 2013;70(3):394-397.

22. Ringelstein M, Ayzenberg I, Harrell J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. *JAMA Neurol*. 2015;72(7):756-763.

23. Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. *Mult Scler Relat Disord*. 2019;9:101920.

24. Carreon GE, Hernandez CR, Castillo TT, et al. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. *Neurologia*. 2019;30:1319-1327.

25. Bree M, Glatter S, Hoffberger R, et al. Two cases of pediatric AQP4-antibody positive neuromyelitis optica spectrum disorder: a case report. *Neurol Neuroimmune Neurol Immunflamm*. 2020;7:56.

26. Kothur K, Wienholt L, Tantsis EM, et al. B cell, Th17, and neutrophil related cerebrospinal fluid cytokine/chemokines are elevated in MOG antibody associated diseases. *Mult Scler*. 2019;25(8):1024-1030.

27. Kaneko K, Sato DK, Nakashima I, et al. CSF cytokine profile in neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised, placebo-controlled, multicentre study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. *J Neuroinflammation*. 2018;15(1):280.

28. Kothur K, Wienholt L, Tantsis EM, et al. Tocilizumab treatment in neuromyelitis optica spectrum disorders. *Neurol Neuroimmune Neurol Immunflamm*. 2020;7:56.
31. Schwake C, Hellwig K, Gold R, Ayzenberg I. Reader response: comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. *Ann Neurol*. 2020;88(2):430.

32. Masuccio FG, Lo Re M, Bertolotto A, Capobianco M, Solaro C. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment. *Mult Scler Relat Disord*. 2020;46:102592.

33. Elsbernd PM, Hoffmann WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review. *Mult Scler Relat Disord*. 2021;48:102696.

34. Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. *J Neuroinflammation*. 2018;15(1):134.

35. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*. 2015;85(2):177-189.

36. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. *Neurology*. 2006;66(10):1485-1489.

37. Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. *Brain*. 2017;140(12):3128-3138.

38. Lopez-Chiriboga S, Sechi E, Buciuc M, et al. Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder. *JAMA Neurol*. 2017;74(12):1575-1577.

39. Pache F, Zimmermann H, Mikolajczak J, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. *J Neuroinflammation*. 2016;13(1):282.

40. Lotan I, McGowan R, Levy M. Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: a systematic review of safety and efficacy. *Curr Neuropharmacol*. 2021;19(2):220-232.

41. Araki M. Blockade of IL-6 signaling in neuromyelitis optica. *Neurochem Int*. 2019;130:104315.
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
Marius Ringelstein, Ilya Ayzenberg, Gero Lindenblatt, et al.
Neurol Neuroimmunol Neuroinflamm 2022;9;
DOI 10.1212/NXI.0000000000001100

This information is current as of November 16, 2021
**Updated Information & Services**  
including high resolution figures, can be found at:  
http://nn.neurology.org/content/9/1/e1100.full.html

**References**  
This article cites 50 articles, 6 of which you can access for free at:  
http://nn.neurology.org/content/9/1/e1100.full.html##ref-list-1

**Citations**  
This article has been cited by 1 HighWire-hosted articles:  
http://nn.neurology.org/content/9/1/e1100.full.html##otherarticles

**Subspecialty Collections**  
This article, along with others on similar topics, appears in the following collection(s):  
- **All Demyelinating disease (CNS)**  
  http://nn.neurology.org//cgi/collection/all_demyelinating_disease_cns  
- **Devic's syndrome**  
  http://nn.neurology.org//cgi/collection/devic_ssyndrome  
- **Optic neuritis; see Neuro-ophthalmology/Optic Nerve**  
  http://nn.neurology.org//cgi/collection/optic_neuritis  
- **Transverse myelitis**  
  http://nn.neurology.org//cgi/collection/transverse_myelitis

**Permissions & Licensing**  
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
http://nn.neurology.org/misc/about.xhtml#permissions

**Reprints**  
Information about ordering reprints can be found online:  
http://nn.neurology.org/misc/addir.xhtml#reprintsus